Sana Biotechnology Return on Equity

Sana Biotechnology (SANA) currently reports a ROE of -137.04%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Sana Biotechnology's ROE history and peer comparisons.

Sana Biotechnology's ROE of -137.04% is lower than the Healthcare sector average of 21.67%. That is roughly 732.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sana Biotechnology's current -137.04% should be judged against Healthcare norms (sector average: 21.67%) and against SANA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -137.04%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Sana Biotechnology, and consider following SANA for alerts when major investors trade the stock.

Sana Biotechnology is classified in the Healthcare sector. On ROE, it currently shows -137.04% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SANA with unrelated industries.